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I. INTRODUCTION 
The scientific 1 iterature that has been described within this document was 
originally compiled as appendix material for the Human Use Research Committee 
Protocol entitled "A Preliminary Evaluation of the Efficacy of Lecithin in the 
Modulation of Motion Sickness Susceptibility." It was recognized that this 
literature would be of considerable value to investigators working on the 
problems of space motion sickness and especially to neurophysiologists and 
pharmacologists who might need additional understanding of neurochemical 
mechanisms related to motion sickness or the drugs used to treat and prevent 
motion sickness. Accordingly, the original text has been reproduced here with 
minimal edition and supplemented with a Table of Contents and a comprehensive 
Index. The following pages will present a detailed description of motion 
sickness, the drugs currently used to treat it, and the metabolic relation-
ships between acetylcholine (ACh) and the anti-motion sickness drugs. Topics 
will include a pharmacological and neurochemical description of scopolamine 
and the precursor-product relationship between choline and ACh. The roles of 
lecithin and its metabolic products in the regulation of the levels of neuro-
transmitters are characterized as a possible means by which cholinergic neuro-
chemistry can be ;nodulated. A brief discussion of the pharmacodynamics and 
side effects of lecithin administration in man is presented as well. Summari-
zing, sufficient information is provided to design and justify experimental 
research on the central cholinergic system in man. 
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II. HISTORICAL AND SCIENTIFIC BACKGROUND OF THE RESEARCH 
A. MOTION SICKNESS - AN OVERVIEW 
The potential incidence of space motion sickness represents an important 
operational concern during space Shuttle missions. Data from the U.S. and 
U.S.S.R. manned space programs clearly indicate that without appropriate 
intervention up to 40% of the astronauts will experience space motion 
sickness (Graybie1 et a1, 1974; Hornick, 1979; Matsnev, 1980). Various 
approaches to the problem of treatment and prevention of motion sickness 
are currently under study. These approaches include: pharmacological, 
vestibular adaptation training, and biofeedback training procedures. 
Pharmacological management is presently the most convenient and effective 
approach to the problem. Orally administered combinations of scopolamine 
pl us amphetami ne and promethazi ne pl us ephedri ne have been shown to be 
highly efficacious in preventing motion sickness (Wood and Graybiel, 1968; 
Graybie1 et!i, 1975; Graybie1, 1979; Sauerland et!i, 1979; Wood, 1979). 
Such oral .medications are relatively short acting and ineffective if 
administered after symptoms have appeared. The identification of a long 
term, prophy1 actic drug for use in space fl ight is of primary concern. 
Such a drug must afford good, reliable protection, low incidence of side 
effects, and be easy to administer. 
B. MOTION SICKNESS.PHARMACOLOGY - SCOPOLAMI~_ 
Scopolamine is one of the drugs of choice for the treatment and prevention 
of space motion sickness. The drawbacks to its use include such side 
effects as central nervous system depression, dry mouth, and loss of 
visual accommodation. Furthermore, scopolamine is only effective medi-
cat i on for a few hours when it is admi ni stered by convent i ona 1 routes (oral, sublingual, injection). The Neuroscience Laboratory at the Johnson 
Space Center is currently evaluating the efficacy of transderma1ly admin-
istered scopolamine as an alternative route of drug delivery. A consider-
able body of literature has accumulated. The transderma1 delivery system 
has been characterized (Shawet a1, 1976; Chandrasekaran and Shaw, 1978; 
Shaw and Urquhart, 1980) and tests of the ability of the system to modu-
late motion· sickness susceptibi1 ity have been performed (Graybie1 et !i, 
1976; Shaw et a1, 1977; Graybiel, 1979; McCauley et al, 1979; Price et al, 
1979; Graybie1et al, 1981; Laitinen et a1, 1981; Wurster et a1, 198T). 
There are indications that this longeracting transderma-1-therapeutic 
system (TTS) may be effective in the prevention of motion sickness and 
cause fewer side effects than oral scopolamine. 
Unfortunately, an even larger body of literature indicates that the 
administration of scopolamine to man can cause impairment of memory (Crow, 
1979; Jones et al, 1979; Liljequist and Mattila, 1979; Mewa1dt and 
Ghoneim, 1979;Peterson, 1979; Rassmusson and Dudar, 1979; Rauca et a1, 
1980), sleep disturbances (Amatruda et a1, 1975; Sitaram et al, 1978; 
Gill in et !i, 1979), and prenatal tOxl c Tty ( Campbell and Rami rez, 1980; 
Evens and Leopold, 1980). A detailed account of the neurophysiological 
and neurochemical actions of scopolamine is presented in Section E. The 
complexity of the effects of scopolamine on the cholinergic nervous system 
(Section E) underscores the problems inherent in the understanding and use 
of this drug. The latter sections of this report will indicate the 
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possible value of manipulation of the cholinergic system through means 
other than by non-specific receptor blockade. Specifically, modulation of 
the cholinergic system by control of the availability of choline will be 
considered in detail {Section F}. 
C. NEUROCHEMISTRY OF STRESSFUL MOTION 
It is reasonable to suggest that chol inergic or histaminergic neuro-
transmission may be elevated during stressful levels of motion. This 
suggestion is supported by observations that antichol inergic or anti-
histaminergic drugs are effective in the treatment of motion sickness 
{Wood and Graybiel, 1968; Graybiel et al, 1975; Wood, 1979}. Increased 
turnover of either one or both of these-neurotransmitters could be a sign 
of increased demand for that neurotransmitter, demand for the biosynthetic 
precursors to these neurotransmitters {choline or histidine}, or may 
instead signal a pathological accumulation of neurotransmitter or its 
metabolic products. 
The admini stration of either scopol amine or promethazi ne to cats effec-
tively reduces the spontaneous firing rate of vestibular nuclei. Natural 
stimulation of the labyrinth normally increases or decreases the firing 
rate of individual neurons in the vestibular nuclei and scopolamine 
suppresses these changes in firing rate {Jaju et al, 1970; Jaju and Wang, 
1971; Matsuoka et al, 1975}. These observations are outwardly consistent 
with the demonstratTOn that ACh excites the majority {80%} of the cells in 
the lateral and medial vestibular nuclei in the cat {Kirsten and Sharma, 
1976}. These findings suggest that sensory information originating in the 
hair cells of the vestibular apparatus is relayed directly to the 
vestibular nuclei via cholinergic neurons. Blockade of cholinergic 
{muscarinic} receptors by scopolamine would hypothetically attenuate the 
excess transmission that occurs along this central nervous system pathway 
during stressful motion. This is the simpl ist model that explains the 
data presented so far, but unfortunately it appears to be inaccurate. 
What actually appears to be happeni ng is a compl ex i nteracti on between 
cholinergic, noradrenergic and primary sensory afferent inputs in the 
vestibular nuclei. The interaction is closely related to central nervous 
system mechanisms of cortical arousal, sensory integration and emotional 
{visceral} response. These processes are not well understood. An attempt 
is made in Section E to define the complex interaction described above, 
but unfortunately "pl ain engl ish" summaries of the original research 
findings {Section E} are not often possible or are hypothetical at best. 
The neurophysiological picture is further complicated by the existence of 
an efferent cholinergic loop that modulates the output of the hair cells 
of the vestibular apparatus {Kirsten and Sharma, 1976; Rossi et al, 1980; 
Goldberg and Fernandez, 1980}. Presumably, these receptors coula-also be 
parti ally blocked by scopol amine even though they tentatively have been 
identified as nicotinic rather than muscarinic receptors {Kirsten and 
Sharma, 1976}. Muscarinic and nicotinic acetylchol ine receptors are two 
classes of cholinergic receptors that are distinguishable by their pre-
ferential interaction with the drugs muscarine and nicotine. {Scopolamine 
is a muscarinic agent}. Theoretically, it should be possible to inhibit 
the output of peri pheral hai r cell s while simultaneously blocki ng the 
afferent excitatory input to the vestibular nuclei by employing two drugs; 
each one selective for only one class of receptor. 
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Presently there are few clues as to why both cholinergic and histaminergic 
antagonists should be effective in the treatment of motion sickness. The 
next section examines the relationship between these two transmitter 
systems. 
o. ACETYLCHOLINE AND HISTAMINE IN VESTIBULAR SYSTEM FUNCTION 
What is the rel ati onship between chol i nergic and hi staminergic neuro-
transmission with respect to the possible neurochemical mechanisms under-
lying stressful motion? Neurophysiologically, both anticholinergics, such 
as scopolamine and atropine (Jaju et al, 1970; Matsuoka et al, 1975) and 
antihistaminergics, such as diphenhydramine and dimenhydrinate (Jaju and 
Wang, 1971), suppress the activity of the cat's vestibular nuclei. These 
drugs effectively reduce both the spontaneous as well as the electrically 
or physically induced changes in the firing rate of vestibul ar neurons. 
Nowak et al, (1977) has presented experimental evidence favoring the 
hypothesi s that histamine increases chol inergic activity through inter-
action with H-1 receptors (which may reside on cholinergic neurons). This 
idea is consistent with reports that antihistamine poisoning is reversed 
by physostigmine, a drug that inhibits ACh catabolism (Cowen, 1979). 
A complementary relationship exists between cholinergic and dopaminergic 
pathways in the central nervous system that is well characterized. Gen-
erally, one system holds another in check. When one system is either over 
or underactive, as typified by diseases such as Parkinsonism and 
Huntington's Chorea, the reestablishment of behavioral normalcy is accom-
plished either by stimulating the deficient transmitter system or by in-
hibiting the overactive system. Functionally opposed neurochemical mech-
anisms are natural counterparts of biological control systems. The best 
understood system is perhaps the autonomic sympathetic-parasympathetic 
nervous system. Other systems exi st that operate at other 1 evel s of 
complexity and subtletly. Section E will examine some neurophysiological 
pathways that fall into this category. Section F will discuss some neuro-
transmitter systems that are functionally linked to the individual's state 
of nutrition. Modification of neurochemical systems by "environmental" 
chemicals (i.e., food) has been used to beneficially modulate the aberrant 
transmitter systems in diseases like Parkinsonism and Huntington's Chorea. 
If histamine increases cholinergic activity, as suggested above, it should 
be possible to demonstrate the existence of a functional relationship 
between histaminergic and dopaminergic neurons. Amphetamine is an 
effective drug in the treatment of motion sickness (Wood and Graybiel, 
1968; Graybiel et al, 1975). and exerts its principal pharmacological 
action through the stimulation of dopaminergic neurons. Since the admin-
istration of histidine was found to antagonize the action of amphetamine (Muley et al, 1979), this provides some evidence that the two transmitter 
systemsare functionally 1 inked, and that hi stidine may be effective in 
modulating levels of histamine. 
The following section elaborates on the neurotransmitter systems effected 
by scopolamine. 
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E. NEUROCHEMISTRY AND PHYSIOLOGY OF MOTION SICKNESS: NEUROPHARMACOLOGY OF 
SCOPOLAMINE AND AMPHETAMINE 
1. Introduction 
Considerable evidence has 1 inked scopolamine's central action with 
modification of cholinergic neurochemistry. Scopolamine is classical-
ly regarded as an anticholinergic drug whose principal pharmacological 
action is blockade of cholinergic receptors. This action accounts for 
some of its side effects (dry mouth, loss of visual accommodation, and 
central nervous system depression) and relates to its effects on 
motion sickness. 
The neurochemical actions of scopolamine are more complex than the 
term "anti-muscarinic" describes. Specifically, the response of dif-
ferent populations of cholinergic neurons to acute doses of scopola-
mine vary according to the brain region examined; some regions show an 
increased turnover rate of acetylcholine (ACH) (Wood and Cheney, 
1979), others demonstrate increased populations of post-synaptic re-
ceptors (Ben-Barak and Dudai, 1980). Although some brain regions 
reveal elevated concentrations of ACH, total brain ACH levels general-
ly fall. Considerabl e evidence correl ates changes in chol inergic 
activity with changes in dopaminergic and noradrenergic activity as 
well (Mason and Fibiger, 1979; Stephens and Herberg, 1979; Engberg and 
Svensson, 1980). Together these considerations make it difficult to 
understand the exact mechanism(s} of action of scopolamine in the 
treatment of motion sickness and suggest that pharmacological 
manipulation of cholinergic function by other means may prove 
worthwhil e. Mani pul ation of other neurotransmitter systems, such as 
the dopaminergic, adrenergic or hi staminergic system, is al ready of 
therapeutic value as exemplified by the use of promethazine (an 
antihistaminergic) and amphetamine (a sympathomimetic). 
Recently, evidence has accumulated suggesting that activity within 
some neurotransmitter systems al so can be mani pul ated by regul ating 
the availability of precursors. This literature will be presented 
later in this appendix (Section F). This section will characterize 
one way to pharmacologically manipulate the chol inergic system that 
may prove worthwhile. 
The following section is intended to present experimental findings on 
the neurophysiology and neuroanatomy of pathways in the central 
nervous system that are involved in the express'ion of motion sickness, 
or perhaps more accurately, involved in transmission of sensory infor-
mation away from the vestibular apparatus. The neurophysiological 
changes illicited by antimotion sickness drugs are reviewed also. 
2. Neurophysiology and Neuroanatom~ 
The initial neuronal events that follow a motion stimulus are fairly 
well understood (see Figure I). Stimulation of the hair cells in the 
vestibular apparatus of the inner ear by the motion stimulus results 
in increased or decreased output from the hair cell depending on the 
direction of motion and the specific hair cell considered (Goldberg 
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and Fernandez, 1971; Budelmann, 1979). This arrangement allows fine 
discrimination of direction and magnitude of motion. The neurotrans-
mitter substance that is released by the hair cells to stimulate the 
primary sensory afferents is unknown. There is evidence against ACh 
or norepinephrine being that transmitter (Matsuoka and Domino, 1975; 
Drescher, 1981) and some speculation and evidence that GABA, glutamate 
or Met-enkephalin might be involved (Flock and Lam, 1974; Meza et al, 
1981; Bobbi n et a 1, 1981; Drescher, 1981; Hoffman et a 1 , 1981; 
Wentho 1 d et !i;198I). - -
Afferent output from the vestibular apparatus is relayed to the 
vestibul ar nucl ei in the brain stem. The neurotransmitter rel eased 
onto these nucl ei by the primary sensory afferents is also unknown. 
Ampl e hi stochemical and pharmacological evidence suggests that ACh 
functions as an afferent neurotransmitter in the vestibul ar nuclei. 
Because of the multiplicity of projections to the vestibular nuclei, 
and especially the abundance of non-labyrinthine synap.tic connections, 
the association of the primary afferent pathway or any pathway with a 
specific neurotransmitter is difficul t. According to the work of 
Kirsten and Sharma (1976), ACh excites 80% and 86% of the neurons 
located in the medial and lateral vestibular nuclei of cats, 
respectively. 
The medial vestibular nucleus in the cat receives projections from the 
semicircular canals and descending afferents from the nucleus of 
Caja1; a pathway involved in the modulation of head and eye movements 
(Markham,1972). However, it is unlikely that the input from the 
semicircular canals is cholinergic (Kirsten and Schoener, 1973; 
Matsuoka and Domino, 1975). The afferent input from the nucleus of 
Caja1 is probably noradrenergic. Norepinephrine and amphetamine 
inhibit 75% of the cells in the medial vestibular nucleus. Phentola-
mine, an a-blocker, does not block the inhibitory response to 
norepinephrine. This suggests that the nucleus processes B-adrenergic 
receptors simi 1 ar to those possessed by the hi ppocampus (Segal and 
Bloom, 1974). Interestingly, 68% of the cells inhibited by 
norepinephrine and amphetamine were excited by ACh (Kirsten and 
Sharma, 1976). 
The lateral vestibular nucleus in the cat receives afferent input from 
the otolith organs (Schor, 1974). Norepinephrine and amphetamine 
excite 63% of the cells in the lateral vestibular nucleus of the cat 
through interaction with a-receptors. This excitatory input is 
blocked by classical a-blockers such as phentolamine. All of the 
ce 11 s exc i ted by norepi nephri ne and amphetami ne are also exc i ted by 
ACh (Kirsten and Sharma, 1976). 
Application of a motion stimulus to cats has revealed that 35% of the 
neurons in the medial and lateral vestibular nucleus are sensitive to 
motion. The great majority (79%) of these motion responsive cells are 
located in the medial vestibular nucleus. Autoradiographic 
localization of muscarinic cholinergic receptors in rat has indicated 
that the medial vestibular nucleus contains many muscarinic receptors 
whereas the other vestibu1 ar nuclei contain few receptors (Lewi s et 
!i, 1980). The medial· vestibular nucleus receives afferents from the 
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semicircular canals. The lateral vestibular nucleus responds to 
reticular formation stimulation. This excitatory response is 
primarily nicotinic and can be blocked by the nicotinic antagonist, 
mecamylamine, but not by the peripherally acting antagonist, 
methadini um. L-Dopa or amphetamine enhances the excitation of these 
neurons in the cat by stimulation of the reticular formation (Matsuoka 
and Domino, 1975). Previous studies have indicated that the neural 
output or firing rate of the vestibular afferents, vestibular nuclei 
and vest i b ul ar related cerebe 11 urn in the dogfi sh is pro port i ona 1 to 
the degree of motion stimulation (Montgomery, 1980). The spontaneous 
discharge rate of the cat's lateral vestibular nucleus (19.8 ± 0.9 Hz) 
is not influenced by a spinal cut (18.0 ± 1.6 Hz) but is decisively 
lowered by scopolamine (Matsuoka et al, 1975). Despite the 
involvement of ACh in the neurochemistryof the vestibular nuclei, 
very little choline acetyl transferase is found. This contrasts 
strongly with the cranial motor nuclei which are very high in choline 
acetyl transferase (Kobayashi et al, 1975). Further discussion of the 
role of· choline acetyltransferase-in the biosynthesis of ACh will be 
deferred to section F (Choline-ACh Relationships). 
It is poss i b 1 e to e 1 imi nate norepi nephri ne as the primary afferent 
neurotransmitter in the vestibular nuclei because there is no 
correlation between the sensitivity of the nuclei to motion and the 
effect of iontophoretically appl ied norepinephrine or amphetamine. 
Secondly, depleti on of brain catechol amines by reserpine does not 
block synaptic transmission· and there is no decrease in the number of 
cell s respondi ng to accel eratory motion. Lastly, ACh does not mimi c 
the response to norepinephrine or amphetamine. 
It is possible to el iminate ACh as the primary afferent transmitter 
because anticholinergic agents are without effect on the field 
potentials evoked by VIIIth nerve stimulation. Hence, the sites at 
which antimuscarinic agents act to depress the activity of vestibular 
nuclei must be other than those in the afferent pathway leading 
directly from the labyrinth to second order vestibular neurons. The 
well-documented synaptic complexities present within the vestibular 
nuclei, especially the abundance of non-labyrinth synaptic connec-
tions, suggests a complex neuronal interaction. The many observations 
of the infl uence of the reticul ar formation on vestibul ar activity 
provides evidence that the inhibition of vestibular units by scopol-
amine is the result of a modified input from the reticular formation 
(Kirsten and Schoener, 1973). The possible roles of the reticular 
formati on and other pathways that are i nfl uenced by scopo 1 ami ne and 
amphetamine will be considered later in this section. 
3. Labyrinth Efferents 
The efferent innervation of the hair cells in the lateral line organs 
of lower vertebrates (Russell and Roberts, 1974; .Flock and Russell, 
1976) in the mammalian cochlea (Wiederhold, 1970; Bobbin and Konishi, 
1974) and in the frog (Gribenski and Caston, 1976) is cholinergic and 
inhibits afferent outflow from the sense organ. This chol inergic 
effect is blocked by curare and partially blocked by atropine. An 
increase in the conductance of chloride channel s residing on the 
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sensory hair cells is the proposed mechanism by which ACh inhibits 
afferent outflow (Rossi et al, 1980). This change in conductance 
which is measured on thehair cell as an inhibitory postsynaptic 
potential change means that there is a drop in the impedance across 
the hai r celli s membrane. It follows, therefore, that small changes 
in receptor currents in response to sensory stimulation would generate 
lower transmembrane voltage changes and a lower probability of pri-
mary sensory afferent di scharge. These authors have specul ated that 
efferent control of the semicircular canal can extend the dynamics of 
this sensory organ to a wider range of stimulus intensities. It has 
been demonstrated that a single efferent neuron innervates many hair 
cells, irrespective of their directional sensitivity, so that sensory 
activity can be controlled peripherally at the receptor level. It has 
been estimated that the activity of some 10,000 to 20,000 vestibular 
afferents (Gacek and Rasmussen, 1961) is modulated by only 400 to 600 
efferent neurons (Gacek et al, 1965; Gacek and Lyon, 1974; Warr, 1975; 
Goldberg and Fernandez, 1980). 
Goldberg and Fernandez (1980) have presented convincing evidence that 
efferent modulation of the hair cells in the squirrel monkey (Saimiri 
sci ureus) is excitatory rather than i nhi bitory. The mai n efferent 
group is a circumscribed column of cells interposed between the 
abducens and the superior vestibul ar nuclei which they designated 
group e. Because the vestibular afferents have a potential dynamic 
range of 0 to 400 spikes per second but usually operate in the lower 
end of the range (Goldberg and Fernandez, 1971; Fernandez and 
Goldberg, 1976), these authors have speculated that efferent excita-
t i on extents the dynami c response range of the sensory system to 
expected motion. If the resting discharge rate of the system was not 
elevated, large accelerations in one direction would cause the output 
of some sensory elements to drop to zero with a consequent loss in 
linear response. This is because the system is operating under normal 
conditions of postural maintenance at a low level of resting output 
and because motion in a given direction affects the direction of 
change in discharge rate differently depending on the particular hair 
cell examined (Goldberg and Fernandez, 1971; Budelmann, 1979). 
According to these authors, the extension of the dynamic range through 
efferent stimulation would not only assure a linear response to sen-
sory stimulation of those cells whose output is decreased by a parti-
cular direction of motion, but al so might increase the drive to the 
vestibulo-ocular reflex, for example, so that a readiness to respond 
to anticipated angular accelerations is maintained. These rationali-
zations are consistent with the observations that little topographic 
specificity exists between individualefferents and the afferents 
whose discharge they modify. 
A biological explanation for the presence of excitatory efferents in 
the squirrel monkey and most likely in the cat as well (see Goldberg 
and Fernandez, 1980) is not at all difficult in light of the foregoing 
and the fact that inhibition of lateral line output in a swimning 
invertebrate would be the appropriate response to prevent overstimula-
tion of receptors designed to detect local movements of water. Neuro-
physiologically, it has been proposed that an efferent action on the 
target cell, rather than on the hair cell itself, would facilitate 
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discharge of primary sensory afferents. Further investigation of the 
mechanisms are warranted. 
Experimentation which entails a precursor load strategy, may prove to 
be of therapeutic value in the prevention of motion sickness because 
it makes available to the nicotinic efferent nerve ending a greater 
supply of the transmitter, ACh. There is evidence that chol ine 
administration not only elevates the amount of stored ACh at the 
presynaptic nicotinic nerve terminal, but also increases the number of 
nicotinic receptors that are responsive to this ACh on the 
postsynaptic membrane (Morley et~, 1977). 
4. Scopolamine and Amphetamine: Effects on Cortex 
Amphetamine is a anti-motion sickness drug that has been proven effec-
tive in the prophylactic treatment of motion sickness. Combinations 
of scopol ami ne and amphetamine, or promethazi ne and amphetami ne are 
more effective than either scopolamine, promethazine or amphetamine 
alone (Wood and Graybiel, 1972). Furthermore, reversal of the central 
nervous system depression that often follows the use of scopolamine or 
promethazine is regarded as an additional advantage of amphetamine. 
It may be possible to ascertain which neurophysiological effects 
comprise the anti-motion sickness actions of these drugs by comparison 
of the neurophysiological effects of each drug. The following para-
graphs will present detailed accounts of the neurophysiological 
actions of amphetamine and scopolamine. Very little data is available 
on the actions of promethazine. 
Scopol amine increases the turnover rate and output of ACh in the 
cerebra 1 cortex and synchroni zes the EEG in both the rat and cat (Nistri et al, 1974; Mantovani et al, 1980). Amphetamine also 
increases-rhe~urnover rate and output of ACh in the cortex but causes 
activation of EEG (Nistri et al, 1972, Schmidt, 1976). Both drugs 
reduce absolute concentratfOrisof ACh in cortex (Schmidt, 1976; Wood 
and Cheney, 1979). Changes in cortical neurochemistry can be related 
to man's state of consciousness because the cerebral cortex is 
recogni zed as the seat of consc i ousness. Levels of consc i ous 
awareness can be roughly correl ated with the degree of cortical EEG 
desynchronization (or activation). Further attention will be given to 
the neurophysiological mechanisms that control cortical activity 
because of the need to control the CNS depression that often follows 
anti-motion sickness medication. 
Stimulation of the midbrain ascending reticular formation causes 
desynchronization of the EEG and increases ACh output in the cortex 
several fold. The course and distribution of acetylcholinesterase -
containing fibers in the forebrain suggests that they form the ana-
tomical basi s of the ascending reticul ar activating system which is 
responsible for electrocortical arousal. This system is not wholely 
responsible for arousal of the animal since blockade of chol inergic 
terminals at the cortical level (by scopolamine) is not sufficient to 
maintai n a synchroni zed EEG. Nonchol inergic corti copetal fibers are 
al so derived from the reticular thalamic nucleus. Evidence suggests 
that electrocortical arousal is mainly a cholinergic phenomenon, 
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mediated by the corticopetal radiations of the ascending chol inergic 
reticular system. Behavioral arousal, on the other hand, may involve 
subcortical pathways, not all of which are chol inergic (Shute and 
Lewis, 1967). There is evidence that monoamines released by ampheta-
mine have an inhibitory effect on synaptic transmission in the cortex. 
This action opposes that of the cholinergic system but its prominence 
is not nearly as great as that of the chol inergic system. Interpre-
tation of the foregoing confl ict in the context of the neurological 
consequences of administration of scopolamine and amphetamine is not 
problematical if one invokes the following assumptions: First of all, 
the CNS depression that follows scopolamine is directly related to 
dimi ni shed "transmi ssion" at the cortical 1 evel. Because scopol amine 
is blocking the receptors, and thus "transmission", the compensatory 
ri se in ACh 0 utput may be regarded as an attempt by the system to 
reestablish equilibrium; that is, to overcome the blockade. Secondly, 
the effects of amphetami ne on ACh re 1 ease is probably more closely 
related to its effects on subcortical systems such as the limbic 
system (discussed below) or the brain stem reticular activating 
system. 
5. The Limbic System 
The limbic system is a subcortical system that also is profoundly 
affected by both scopolamine and amphetamine (Figure 2). The limbic 
system includes the hippocampus, the amygdaloid nucleus, the 
hypothalamus (especially the mammillary bodies), and the anterior 
nucleus of the thalamus. The fornix, mammillothalamic tract, and 
stria terminalis are the fiber bundles of the limbic system. It is 
known as the "visceral brain" because it is functionally associated 
with emotional aspects of behavior related to survival of the 
individual and the species, together with "visceral responses" 
accompanying these emotions, and the brain mechanism for memory. The 
visceral responses to activity within the 1 imbic system are mediated 
mainly through the hypothalamus and include changes in respiration, 
gastrointestinal movements and secretion, piloerection, and pupillary 
dilation. Understanding of neurophysiological regulation of visceral 
functions is primary to elucidation of the neural components of motion 
sickness and the neuropharmacological bases of anti-motion sickness 
drug therapy. 
Electrocortical arousal by reticular stimulation of hippocampectomized 
cats is difficult and, unlike the arousal obtained in normal animals, 
lasts only for the duration of the stimulus. lt is likely that these 
hippocampal effects are achieved by influences acting on some part of 
the brain external to the hippocampus, rather than as an intrinsic 
property of the hippocampus itself. A major output from the hippo-
campus passes directly through a relay in the mamillary body to ele-
ments of the chol inergic 1 imbic system which connect directly with 
medial cortex or, through links with the ascending cholinergic retic-
ul ar system, with the 1 ateral cortex of the cerebral hemi spheres 
(Lewis and Shute, 1967). Thus, the limbic system may be critical to 
maintaining alertness. 
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Relationship of Ascending Reticular, 
Limbic, Hypothalamic and Cortical Systems 
Cortex------~~~\ 
Input from 
reticular formation 
Body of forn ix-~:S--;;-;;~:::~~4~~~~ ~~IJ~~iL...-Septum 
~!!!!--~----Anterior thalamus 
\II!----Fornix Vomiting center----~~~-~­
Mammillothalamic tract-+.~~!----~~---~ re;:..,.....,&.;iII~---Paraventricular 
nucleus 
Area postrema---~~~~-....I:_- "Jt,.J~t!-----Anterior com miss u re 
~~inir----Anterior nucleus 
Nucleus intercalatu5--~-~~~----~'J/.; ~~Il4~\~-=--=--=-==PreOPtic area 
flI Ventromedial nucleus 
Fimbria ~~~--Supraoptic nucleus 
Hippocampus------~~~ ~~~II~ 
~----Pituitary gland 
Figure 2 
Although superficially both nicotine and muscarinic agonists induce an 
alert EEG, their effects differ in several important aspects. Nico-
tinic arousal of the EEG may depend on the intactness of the reticular 
formation, as compared with the more diffuse arousal of the EEG caused 
by muscarinic agonists (Domino et ~, 1967). 
6. Scopolamine and Amphetamine: Effects on Limbic Structures 
Scopolamine increases ACh outflow in the cerebral cortex by an action 
on subcortical, limbic structures (Figure 2). Cortical release of ACh 
by scopolamine is blocked by lesions in the septum, fornix, or fimbria 
of cats and rats (Nistri et al, 1972, Mulas et al, 1974, Mantovani et 
al, 1980) and by corticalundercutting (Nistnetal, 1972). Lesions 
or the septal nuclei destroy the major chol inerglc cell bodies that 
send afferents to the hippocampal limbic structures. Lesions of the 
fornix (and fimbria) block the non-cholinergic output of the 
hippocampus. It is believed that this non-cholinergic outflow 
eventually reaches the ascendi ng chol i nergic reticul ar system which 
projects to the cortex. It is reasonable to suggest that this 
interaction of the limbic system with the ascending reticular system 
is essential to the cats' ability to maintain arousal. If such a 
mechanism does exist, it most likely involves a pathway originating 
from the hippocampus that travels with the fibers of the fornix to the 
mammillary bodies in the hypothalamus. The major efferent connections 
of the mammillary bodies are via the mammillothalamic tract to the 
anterior thalamic nuclei. The nuclei of the anterior thalamus are 
non-specific nuclei that have extensive reciprocal connections with 
the association cortex (cingulate gyrus) (Mountcastle and Poggio, 
1968; Bard, 1968, Mountcastle, 1968; Barr, 1974). Lesions of septum, 
fornix, fimbria and cortical under,cutting may all impair the role that 
this thalamic radiation plays in maintaining arousal. 
Amphetamine increases ACh outflow in the cerebral cortex by an action 
that also is dependent on an intact limbic system since septal lesions 
prevent the increase (Nistri et~, 1972). Amphetamine induces short 
term increases in 1 eve 1 of ACh in the stri atum and cerebe 11 urn and 
simultaneous decreases in the level of ACh in cortex and hippocampus 
(Schmidt, 1976). This is consistent with amphetamine-induced changes 
in the turnover of ACh. Although amphetamine can activate EEG by 
stimulation of the midbrain reticular formation, an intact reticular 
format ion is .not necessary for the drug effect. Ab 1 at i on of the 
septum, which prevents amphetamine el icited rel ease of ACh in the 
cortex, does not block the EEG activation. Apparently, at least two 
mechanisms exist for EEG activation by amphetamine. 
Many collateral pathways are derived from the pathways linking hippo-
campal efferents with the anterior thalamus. Fibers that leave the 
fornix and terminate in the anterior hypothalamic nuclei and the 
nucleus intercalatus in the mammillary bodies are of particular 
interest to the study of motion .sickness. The anterior hypothal amic 
nuclei exert a major influence on the visceral organs. The predomin-
antly parasympathetic outflow from this region will increase sweating, 
vasodilation, salivation, and peristalsis of the gastrointestinal 
tract whi 1 e decreasi ng heart rate and blood pressure. All of these 
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peripheral effects can and do occur in motion sickness. The nucleus 
intercalatus sends efferent fibers to the area postrema which in turn 
innervates the "vomiting center" (Reason and Brand, 1975; Vigier and 
Rouviere, 1979). The apparent blockade of the septohippocampal path-
way by scopolamine could both diminish the peripheral symptoms of 
motion sickness and block neuronal pathways to the vomiting center. 
Stimulation of the (mesencephalic) reticular formation increases ACh 
release from the hippocampus. Section of both fornices does not alter 
spontaneous release of ACh from the hi ppocampus, but does prevent 
release mediated by the reticular fonnation. The administration of 
amphetamine acts exactly like stimulation of the reticular fonnation; 
the increased release of ACh is al so prevented by section of the 
fornices. Scopolamine also increases ACh release from the hippo-
campus. This release occurs following topical applications of the 
drug and occurs with or without cut fornices. 
Wood and Cheney (1979) have attempted to distinguish whether a 
neuronal feedback loop or a presynaptic muscarinic receptor mechanism 
could be invoked to explain the actions of scopolamine on the turnover 
rate of ACh in the septo-hippocampal cholinergic pathway. They con-
cluded that the cholinergic systems of the hippocampus and thalamus 
possess sel f-regul ati ng feedback mechani sms that are markedly per-
turbed by muscarinic receptor blockers. The perturbation is expressed 
by a two-fold elevation in the turnover of ACh in the hippocampus. In 
support of this concl usion.,they described experimentation that (I) 
ruled out the presence of presynaptic muscarinic binding sites in the 
hippocampus, (2) negated any role of inhibitory cholinergic neurons in 
the septum, and (3) demonstrated that the blockade of the stimulatory 
noradrenergic input to the septum does not infl uence the increased 
turnover rate of ACh in the hi ppocampus that fo 11 ows scopo 1 ami ne 
administration. The authors suggested that axonal collaterals of the 
cholinergic septal neurons may activate noncholinergic inhibitory 
interneurons which in turn act on the cell bodies. 
7. Conclusions 
The influence of anti-motion sickness drugs on the vestibular nuclei 
i s well doc lITIented. It appears that nei ther ACh nor norepi nephri ne 
are directly involved in primary sensory transmission at the end organ 
(the hair cell) or at the vestibular nuclei, but instead play prom-
inent roles in modulating the activity of vestibular nuclei. The 
involvement of the chol inergic ascending reticular activating system 
and the limbic system with higher nervous system functions is apparent 
as is the relationship of these pathways to the expression of both the 
symptoms of motion sickness and the side effects of the anti-motion 
sickness drugs. Because of the complexity of the central cholinergic 
system and the systems with which it interacts, it is not only diffi-
cult to design a new therapeutic approach to manage motion sickness, 
but it is even perplexing to define the mechanism of action of the 
proven anti-motion sickness drugs. 
The authors want to stress the possibil ity that the "medial II vesti-
bular nucleus may be a site of particular importance in the action of 
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the known anti-motion sickness drugs and, consequently, the medial 
nucleus may play an essential role in the normal neurophysiological 
mechanisms underlying motion sickness. The medial vestibular nucleus 
is distinguished from the remaining nuclei on the basis of its 
afferent input, its response to ACh, norepinephrine and anti-motion 
sickness drugs (see Figure 1). The medial vestibular nucleus receives 
its input from the semicircular canals and from the interstitial 
nucleus of Cajal (Markham, 1972). The latter input is presumably 
noradrenergic and concerns the modul ation of eye and head movements. 
The medial vestibular nucleus is stimulated by ACh and inhibited by 
NE, whereas the lateral vestibular nucleus is stimulated by both 
transmitters (Kirsten and Sharma, 1976). "Muscarinic" chol inergic 
receptors are sparce on the lateral vestibular nucleus but abundant on 
the medial nucleus (Lewis et al. 1980). The equal effectiveness of 
scopolamine (0.6 mg) and amphetamine (20 mg) in the prevention of 
motion sickness favors assessment of the medial vestibular nucleus as 
an important relay station in the expression of motion sickness. The 
fact that 79% of the vestibular neurons that are responsive to motion 
stimuli are located in the medial vestibular nucleus further supports 
this contention (Kirsten and Sharma, 1976). 
The common denominator throughout this section has been ACh; it 
modul ates the activity of peri pheral hai r cell s, central vestibul ar 
nuclei, the parasympathetic autonomic nervous system and other central 
mechanisms as well. The problem with anticholinergic motion sickness 
drugs is that they are nonspecific muscarinic blockers. An alter-
native pharmacological intervention has been suggested that is based 
on the administration of normal dietary constituents. Lecithin or 
chol ine will modul ate chol; nerg;c activity through el evation of the 
circulating levels of choline; the immediate biochemical precursor of 
ACh. The influence of choline on cholinergic function will be dis-
cussed in the next section. Al though the effects of chol ine are 
distinctly different from those of scopolamine, selectivity for the 
cholinergic system is still retained. There is no reason to assume 
that a specific blockade of (a) muscarinic receptor(s) is key or 
essential in the "anti-motion sickness" effects of scopolamine. 
F. THE CHOLINE-ACETYLCHOLINE RELATIONSHIP 
1. Introduction 
Choline and phosphatidylcholine (lecithin) are recognized as effective 
modulators of cholinergic neurochemistry (Cohen and Wurtman, 1976; 
Consolo et al, 1979). Both the levels of ACh in brain and the func-
tional activity of chol inergic neurons (Ul us and Wurtman, 1976; Ulus 
et al, 1977; Haubrich and Pflueger, 1979) are reported to rise shortly 
after a choline or lecithin meal. The action of choline on this 
neurotransmitter system is well establ ished in terms of fundamental 
enzyme kinetics (White and Wu, 1973, Marchbanks and Wonnacott, 1979; 
Fernstrom and Wurtman, 1979), behavioral end points (Wecker and 
Schmidt, 1979), and in clinical disorders of cholinergic function such 
as tardive dyskinesia and Huntington's Chorea (Barbeau, 1978; Kolata, 
1979; Zei sel et~, 1980a). 
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Control of the functional activity of a particular type of neuron or 
at least regulation of the size of individual neurotransmitter pools 
by the physiological precursor substance is not a new idea, nor is it 
restricted to only one neurotransmitter system (Fernstrom and Wurtman, 
1974; Smith et al, 1977; Wurtman and Fernstrom, 1976; Growdon and 
Wurtman, 1978).- Neurons that use ACh, norepi nephri ne and 5-
hydroxytryptamine as thei r chemical neurotransmitter are known to be 
responsive to circulating levels of their respective precursors, 
namely, chol ine, tyrosine (Gibson and Wurtman, 1978) and tryptophan (Fernstrom and Wurtman, 1971). The levels of other important inter-
mediates in brain, namely, histamine and S-adenosylmethionine, also 
appear to be strongly influenced by the availability of their immedi-
ate precursors, histidine and methionine (Taylor and Snyder, 1972; 
Rubin et al, 1974; Polland et al, 1974)). What appears to be emerging 
in currenr-thought is the concept that the brain is not an organ that 
is metabolically isolated from the rest of the body by a blood-brain-
barrier, but rather, responds dynamically to both peripheral chemical 
and sensory inputs (Fernstrom and Wurtman, 1974). It is believed that 
this responsiveness is accomplished through neurochemical sensing 
mechanisms such as those embodied by neuronal precursor-product rela-
tionships as described in this section. 
2. Overview of Factors Which Control Synthesis of Acetylcholine at the 
Nerve Terminal 
a. Choline Acetyltranferase and Acetylcholine Synthesis 
Choline is the physiological precursor of ACh whose acetylation is 
catalyzed by the enzyme choline acetyl transferase (CAT) using 
acetyl-CoA as the acetate donor. The enzyme is nonna 11 y very 
unsaturated with its substrate chol ine. Its K for chol ine is 
about 400 ~M, whereas brain choline levels vary b~tween 35 and 100 
liM (Cohen and Wurtman. 1976). Manipulations that elevate brain 
choline will enhance the saturation of CAT and cause more ACh to 
be synthesized. 
b. Choline and Acetylcholine Synthesis 
Chol ine given intravenously or via the diet sequentially raises 
brain choline and then ACh levels (review: Haubrich, 1979). 
Insignificant amounts of choline can be synthesized de novo in the 
brain (Jenden, 1979; Zeisel et al, 1979). The bram derives its 
choline from the blood in~otfi free and lipid bound (e.g., 
1 ecithi n) form. 
There is some evidence that amphetamine may alter lecithin metab-
olism so as to favor the fonnat~on of free choline. This is 
because the incorporation of ( C) choline into phosphatidyl-
choline was inhibited by amphetamine, whereas phospholipase C 
(which initiates coversion of lecithin into choline) appeared 
uneffected (Hitzemann and Loh, 1973). Although chronic amphet-
amine administration increased choline acetyl transferase in brain (Ho and Gershon, 1972), this observation should not be regarded as 
a direct effect of amphetamine on the chol inergic system. It is 
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more likely that the rise in choline acetyl transferase is a res-
ponse to elevated noradrenergic activity instead. 
c. Choline Intake and Acetylcholine Synthesis 
ACh that is released from the nerve terminal can not be taken up 
by the nerve terminal or any other cell until it is metabolically 
broken down into chol ine and acetate. Abundant suppl ies of ace-
tylcholinesterase are present in the region of the nerve terminal 
to effect this cleavage. A high affinity uptake mechanism exists 
for the transport of choline into the presynaptic terminal. 
Cholinergic neurons appear to be the only cells which possess the 
high affinity uptake system. When chol ine is taken up by the 
nerve, it is used for the synthesis of ACh. The degree to which 
this uptake is coupled to the uptake process is in dispute (50-80% 
is acetyl ated) • There is ample and conv inc i ng ev i dence wh i c h 
demonstrates that the high affinity chol ine transport system is 
responsible for a significant portion of ACh synthesized in brain, 
in vivo (review: Simon et ~, 1976; Fisher and Hanin, 1980). 
d. Choline Uptake and the Functional Activity of Cholinergic Neurons 
The uptake of choline by the nerve terminal is proportional to the 
turnover rate of ACh (Kuhar and Murrin, 1978). Drugs which are 
effective in altering the turnover r~te of ACh, such as scopol-
amine, atropine, physostigmine and A -tetrahydrocannabinol, also 
cause corresponding changes in choline uptake. The neurochemical 
mechanism underlying this effect is not well understood. There is 
some evidence that intracellular stores of ACh regulate the func-
tional activity of the chol ine transport site through occupation 
of the cytosol ic binding sites on the carrier. The competition 
for choline binding sites is diminished upon release of intra-
cellular stores of ACh, such as would follow nerve stimulation (Marchbanks and Wonnacott, 1979). When mice are treated with 
atropine 30 minutes before sacrifice, a dose-dependent increase in 
high-affinity choline uptake can be measured in isolated crude 
synaptosomal preparations that is particularly pronounced in 
hippocampus and cortex but not in striatum (Eckernas et !i, 1980). 
If intracellular levels of ACh participate in the regulation of 
choline uptake, it would follow that choline is accumulated with 
some degree of selectivity by those neurons actively involved in 
transmi ssion. Thus, the pharmacological ~ffects of the admi n-
istration of choline (or lecithin) would differ from that of 
scopolamine in an important respect; that is, scopolamine would 
nonspecifically block all muscarinic receptors, whereas, high 
circulating levels of choline would act as a buffer to the func-
tional acti vity of the chol inergic system. Although a strong 
argll11ent can be made for the association of the side effects of 
scopolamine with its nonspecific blockade of receptors, no such 
argll11ent exists for the correlation of high choline availability 
with a therapeutic benefit of choline in motion sickness. 
Fortunately, there is no strict correlation between muscarinic 
receptor blockade and an anti~motion sickness effect since 
amphetamine (20 mg), is as effective as scopolamine (0.6 ~g) (Wood 
and Graybiel, 1968, 1972). 
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3. Modulation of the Central Effects of Antimuscarinic Drugs by Choline 
A high dose of atropine ordinarily leads to the depletion of ACh in 
cortex and hippocampus, an increased turnover of ACh and accelerated 
uptake of choline. If choline is administered one hour before 
atropine, these changes do not occur (Wecker et al, 1978). Although 
the acute administration of choline reduces the effects of atropine, 
chronic choline loading renders central muscarinic receptors more 
responsive to two effects of atropine, viz., ACh depletion and 
locomotor hyperactivity. These effects could result from altered 
sensitivity or number of receptors (Wecker and Schmidt, 1979). 
4. Conclusions 
The difficulties encountered in attributing a specific set of 
pharmacological actions to the therapeutic benefit of scopolamine in 
motion sickness are a consequence of its many neurochemical actions. 
If depletion of ACh at the peripheral inhibitory synapse compromises 
regulation of the sensory output of the labyrinth, then an elevated 
circulating supply of choline may be of therapeutic value. If 
alteration of the dynamics of cholinergic activity in the cortex and 
hippocampus is responsible for the side effects of scopolamine, then 
chol ine might effectively diminish these side effects as well. It is 
enti rely possibl e that the greatest benefit might eventually derive 
from the simultaneous administration of both choline and scopolamine. 
The experimental testing of thi s hypothesi s wi 11 necessarily have to 
fo 11 ow the determi nat i on of the effects of cho 1 i ne alone and the 
subsequent reassessment of those neurochemical actions of scopolamine 
which are meaningful to the prophylactic treatment of motion sickness. 
G. NEUROCHEMICAL AND NEUROPHARMACOLOGICAL CONTROL OF PITUITARY HORMONES 
1. Relationship of Pituitary Hormones and Motion Sickness 
Eversmann et al (1978) have reported that the stress of motion 
sickness inlman-leads to increased levels of growth hormone, cortisol, 
prolactin and antidiuretic hormone (ADH) in plasma. Plasma levels of 
thyrotropic hormone (TSH) were decreased while the urinary excretion 
of triiodothyroxine and thyroxine increased (Habermann et al, 1978). 
These authors concl uded that ADH secretion was the most sensitive 
indicator of motion sickness and that endocrinological factors in 
general, could be used to evaluate susceptibility to motion sickness. 
However, the increase in .hormone secretion correl ated well with only 
the number of stressful head movements and the i ncreasi ng degree of 
motion sickness within individual subjects. 
Amphetamine influences secretion of TSH and prolactin from the 
pituitary (Lu and Meites, 1971; Ravitz and Moore, 1977; Spindel et al, 
1978). Since this action of amphetamine is augmented by treatments 
that accelerate dopamine synthesis (Clemnens and Fuller, 1979), the 
drug probably exerts its influence on pituitary hormones by releasing 
dopamine (Watkins et ~,1979). It has been fairly well established 
that dopamine is the prolactin inhibitory factor (Caron et al, 1978; 
Weiner and Ganong, 1978). -- --
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TSH, prolactin and growth hormone are three anterior pituitary 
hormones whose modulation by cAMP, brain neurotransmitters, 
hypothal amic rel easi ng factors and peri pheral stress is well 
estab 1 i shed (Spi nde 1 et a 1, 1980) • Growth hormone is released in 
humans by stress (MartTri et ~, 1977) and by ACh in bovine pituitary 
slices (Young et al, 1979). Treatments which increase 
5-hydroxytryptamine-syntnesis in brain, such as administration of the 
prec ursor ami no ac i d, tryptophan, wi 11 enhance growth hormone 
secretion in the rat (Arnold and Fernstrom, 1981). The effects of 
tryptophan on the release of growth hormone in man is not as 
pronounced as that in the rat but is similar (Muller et al, 1974; 
Woolf and Lee, 1977, Glass et ~, 1979). - -
Cortisol secretion is increased by the systemic and intrahypothalamic 
administration of cholinomimetic drugs, and decreased by 
antichol inergic agents (Endroczi et al, 1963; Krieger et al, 1968; 
Cozanitis, 1974; Hillhouse et 21-, 1975). The secr~tion of growth 
hormone ~ vivo may be influenced by cholinergic agents (Blackard and 
Waddell, 1969; Salvadorini et al, 1975, Mendelson et al, 1978). 
Prolactin secretion is usuall~nhTbited by cholinergic-agonists under 
circumstances of active prolactin release (Blake and Sawyer, 1972· 
Grandison et ~, 1974; Lawson and Gala, 1975). Davis and Davis {1980~ 
have reported that the admi ni strati on of methscopol ami ne and 
physostigmine to man did not affect secretion of cortisol, growth 
hormone or prolactin. However, they observed that in those subjects 
who became nauseated or vomited (some of whom received larger doses of 
physostigmine), levels of cortisol, growth hormone and prolactin were 
markedly elevated. These results confirm earlier findings with 
physostigmine (Sachar et al, 1977; Carroll, 1978) in which nausea, 
pallor, vertigo and increased sweating were all accompanied by large 
elevations of cortisol, prolactin and growth hormone in plasma. When 
physostigmine is given by slow infusion it is possible to obtain these 
hormonal responses without nausea (Carroll, 1978). 
Muscarinic receptors have been identified in the anterior pituitary of 
both rat and sheep {Burt and Taylor, 1980; Schaeffer and Hsueh, 1980}. 
However, only low levels of acetylcholinesterase have been found in 
bovine anterior pituitary, approximately 2 and 8 percent of whole 
brain levels, respectively (LaBella and Shin, 1968). These muscarinic 
receptors are responsive to chol inergic drugs. Using organ-cul tured 
anterior pituitary, it has been shown that ACh agonists such as 
carbachol and pilocarpine stimulate mitoti,c activity, whereas, 
scopolamine and atropine inhibit mitotic activity {Pawlikowski et al, 
1978}. Since there is no established cholinergic or other innervation 
to the anterior pituitary, the presence there of typical muscarinic 
receptors suggests that ACh reaches the tissue through the hypophyseal 
portal circul ation and may thus have a role in the regul ation of 
pituitary function. 
It is not surprising that hypothalmic neuroendocrine transducer cells 
recei ve neuronal afferents that release monoami nes and ACh or that 
they release hormones in the pituitary in response to these stimuli. 
It is interesting however, that the rates at which neurons synthesize 
5-hydroxytryptami ne, catechol ami nes and ACh depend in part on the 
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availability of their circulating precursors, tryptophan, tyrosine and 
choline, respectively. These are naturally occurring dietary con-
stituents that are transported into the brain from the systemic 
circulation (Growdon and Wurtman, 1978). 
2. Effects of Hormones on Cholinergic Neurochemistry 
Glucocorticoids, insulin and thyroxine exert significant influences on 
cho1 inergic metabol ic processes. Effects on the chol inergic system 
are generally opposite to the effects on catechol aminergic neurons. 
Those hormones that subserve opposing metabolic functions often exert 
opposi ng effects on a gi ven tran smitter system. Speci fi ca lly, 
glucocorticoids stimulate catecholamine biosynthesis, elevate tyrosine 
hydroxylase-specific activity, but depress ACh synthesis and storage 
in a clone of sympathetic nerve-like cells. Insulin opposes the 
acti on of gl ucocort i coids on ACh synthesi s by rai si ng chol i ne 
acety1transferase-specific activity (Schubert et a1, 1980). This 
effect of i nsu1 in has been confi nned in vitro in preparat ions from 
cortex and striatum but not in vivo-. Thyroxine accelerates ACh 
synthesis in cortex in vivo without changing absolute concentrations 
of ACh. This effect does not occur in vitro (Billewicz-Stankiewicz et 
El, 1980). - -
Considerable attention has been given to the possible roles of the 
cho1 i nergi c septo-hi ppocampa 1 pathway and its projections to 
hypothalamic nuclei involved in parasympathetic outflow and the 
vomiting reflex (Section E). Because septal lesions potentiate both 
behavioral and hormonal responses to stress, as measured by pl asma 
levels of corticosterone, growth honnone and prolactin (Seggie and 
Uhlir, 1979), it follows that this pathway may also be involved in 
stress and release of honnones from the anterior pituitary. Further 
evidence for this role is obtained from the discovery of ACTH 
receptors in the septum. Stimu1 ati on of these receptors inhibits 
release of ACh in the hippocampus (Botticelli and Wurtman, 1981). 
H. SUGGESTIVE DATA FROM SKYLAB 
Nine astronauts participated in the three Sky1ab missions; five of them 
demonstrated signs of motion sickness. Hematological studies revealed 
that those astronauts who had echinocyte levels greater than 1% of the red 
blood cell population on either the day before flight or on mission day 3 
or 4 experienced motion sickness symptoms. This correlation prevailed 
dispite the use of anti-motion sickness drugs. Lecithin, lysolecithin, 
and free fatty acids are known echinocytogenic agents. Unfortunately, the 
1 evel s of these factors were not measured duri ng the Skyl ab mi ssions 
(Kimzey, 1977). The presence of elevated plasma lecithin and lysolecithin 
might facilitate the fonnation of ACh and enhance cholinergic function as 
described earlier. This effect could be antagonistic to the anti-motion 
sickness effects of scopolamine. Consequently, altered susceptibility to 
motion sickness may have resulted, at least in part, by this mechanism. 
Another interest i ng ob serv at i on deri ved from data collected duri ng the 
Sky1ab missions concerns the levels of acetylcholinesterase in 
red blood cells. In all cases there was a pronounced decrease in 
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acetylcholinesterase levels following launch. This decrease was greater 
during the Skylab 3 and 4 missions. The absolute levels also were lower 
during these missions in comparison toSkylab 2 (Mengel, 1977). These 
reductions in the levels of acetylcholinesterase might significantly 
inhibit ACh metabol ism in the circul atory system and possibly in the 
central nervous system as well. The astronauts of Skylab 2, as mentioned 
above, did not show any signs of motion sickness. It is entirely possible 
that circulatory levels of acetylcholinesterase playa role in determining 
an individual's susceptibility to sickness induced by stressful motion or 
a zero-gravity environment. 
The neurochemical and neuropharmacological control of pituitary hormones 
has been discussed already {see section G). Eversmann, et al (1978) have 
reported that the stress of motion sickness in man leadsto increased 
secretion of growth hormone, cortisol, prolactin and ADH. Aerobatic 
flight (30 minutes) elevates the serum levels of growth hormone, prolactin 
and free fatty acids in untrained personnel but not in .trained pilots. 
All of the novices experienced dizziness and mild, brief bouts of nausea. 
When either group was subjected to caloric stimulation of the labyrinth, 
dizziness, nausea, and nystagmus followed but no hormonal changes were 
demonstrable (Pinter et al, 1979). When experienced pilots are subjected 
to more strenuous flfgfit--, a late increment occurs in both growth hormone 
and free fatty acid 1 evel s (Pi nter, 1974). It is not cl ear why cal ori c 
irrigation does not el icit any hormonal changes. Further studies are 
needed to clarify the situation. 
Data from the Skylab missions has revealed a 50% rise in growth hormone in 
plasma 3-4 days after launch. The magnitude of this rise is in line with 
results obtained by Pinter (1974). The levels of excretion of urinary ADH 
immediately following launch did not match the results of Eversmann et al 
(1978), however. Levels of ADH were actually diminished following launch 
with the exception of those measurements obtained from Skylab-2 (Leach and 
Rambaut, 1977). Presumably, the shift in fluid towards the head that 
occurs duri ng zero-gravity exerts a stronger infl uence on ADH rel ease. 
The incongruity of the findings early in the Skylab-2 mission is most 
likely explained by the unusually heavy load of work these astronauts had 
in erecting a heat shield outside of the vehicle and by the high environ-
mental temperatures that prevailed. 
Secretion of cortisol is decreased by intrahypothalamic administration of 
anticholinergic agents (Endroczi et al, 1963; Krieger et al, 1968; 
Cozanitis 1974; Hill house et al, 1975)--. Significant elevations of both 
the levels of urinary andpi"asma cortisol occurred inflight and post-
flight. Anti-motion sickness drugs such as scopolamine were taken by the 
crew of Skylab-3 and 4, but were generally ineffective in preventing the 
rise in cortisol. The crew of Skylab-2 received little or no medication 
and yet maintained the lowest levels of urinary cortisol. There appears 
to be no relationship between the changes in the levels of cortisol and 
the administration of scopolamine. Members of Skylab-3, for example, 
demonstrated a rise in urinary cortisol in advance of any anti-motion 
sickness medication. It is interesting, however, that those two crewmen 
who actually vomited during the Skylab missions had the highest levels of 
secretion of cortisol. Level s aT urinary cortisol in these crewmen were 
elevated in excess of 180% by the first day of flight, whereas, levels in 
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members of Skylab-2 ranged from 0-40% higher. Levels of circulating ACTH 
were significantly decreased by the third to fourth day infl ight (Leach 
and Rambaut. 1977). Urinary excretion of cortisol was not increased sig-
nificantly in studies on the ground by stressful head movements in the 
rotating chair (Eversmann et ~, 1978). 
I. SUMMARY AND CONCLUSIONS 
The problems and nature of space motion sickness have been defined. The 
neurochemical and neurophysiological bases of vestibular system function 
and of the expression of motion sickness have been reviewed. Considerable 
emphasis was given to the elucidation of the neuropharmacological 
mechanisms underlying the effects of scopolamine and amphetamine on motion 
sickness. Characterization of the ascending reticular activating system 
and the 1 imbic system has provided cl ues into the etiology of the side 
effects of scopolamine, but more importantly, it has given us inSight into 
the operation and functional activity of the central chol inergic nervous 
system. The interrelationship between central cholinergic pathways and 
the peripheral (autonomic) expression of motion sickness was described. A 
correlation between the stress of excessive motion and a variety of 
hormonal responses to that stress was also detailed. 
The chol inergic system is the conmon denominator in most of the experi-
mental work described above. It is involved in the efferent modulation of 
the vestibular hair cells, as an afferent modulator of the vestibular 
nuclei, and in the activation of cortical and limbic structures. ACh also 
is involved in the expression of motion sickness symptoms and most likely 
underscores a number of the hormonal changes that occur in stressful 
moti on envi ronments. Because of the extensi ve i nvol vement of ACh 
throughout these motion related systems, it is reasonable to expect that a 
potent anticholinergic drug such as scopolamine would exert a significant 
modulatory role in the expression of motion sickness. 
It is both reasonable and likely that the dietary administration of 
pharmacological doses of lecithin would exert a definite modulatory role 
in the expression of motion sickness as well. The effects of lecithin and 
chol ine on the absol ute and functional level s of ACh in brain supports 
thi s rol e. Emphasi s has been given to the accepted use and benefit of 
such an approach in the treatment of several disorders that involve 
abnormal cholinergic neurochemistry (see also Section III). This 
so-called precursor-load strategy is not a new approach and is not 
restricted to just the cholinergic system. The pharmacological 
manipulation of the cholinergic system by the administration of lecithin 
or choline is in large part dependent on the concept that the function of 
the central nervous system is responsive to the nutritional state of the 
organism. It is the opinion of the author that this concept is both 
experimentally founded and intuitively practical. 
The foundation for future experimentation on motion sickness has been 
layed in the course of the above presentation. Specifically, future 
experimentation might include investigation of the effects of drugs that 
modify high affinity choline uptake. Experiments with choline and 
lecithin would provide support for the develolJl1ent and testing of new 
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choline drugs. The advantage to initial experimentation with lecithin is 
that it comprises use of a safe, normal dietary component that has been 
administered for years. 
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III. PHARMACODYNAMICS AND SIDE EFFECTS OF LECITHIN AND CHOLINE ADMINISTRATION 
A. Experimental Plan of Research in Progress at Johns~n~ace Center 
Subjects participating in the experiment will consume 25 grams of 
soy lecithin (90% phosphatidylcholine) per day in 1-2 divided doses. 
Diets will be supplemented with lecithin for 3 weeks at which time 
the final experimental test with the staircase velocity motion 
stressor will be performed. 
B. Background 
Both choline and lecithin supplements have been given to human sub-
jects for the experimental treatment of various disease states 
bel ieved to involve deficient chol inergic activity. This approach 
has resulted in cl inical improvement in the symptoms of tardive 
dyskinesia and Huntington's Chorea (Growdon et al, 1977, 1978; 
Gelenberg et al, 1979; Davis, 1979), with little or-slight benefit 
to those individuals suffering from Friedreich's Ataxia, Gilles de 
la tourette's disease and Alzheimer's disease (Barbeau, 1978). 
Earlier experimentation employed choline almost exclusively to 
effect a rise in serum choline levels. Normal plasma levels of 
choline are 11.2 ± 0.7 ~M (n=19) for normal individuals (Chamberlain 
et ~, 1980). Typically used doses of choline or lecithin signifi-
cantly raise plasma choline to levels in the 23-36 ~M range (Growdon 
et al, 1977, 1978; Chamberlain et al, 1980). Figure 3 best des-
cribes the differences in the response of plasma choline to ingested 
chol ine versus ingested lecithin. Lecithin doses that actually 
contain less molecul ar chol ine than the chol ine supplement elevate 
the levels of choline in plasma for a considerably longer period of 
time than choline alone (Ziesel et~, 1980 a,b). 
C. Side Effects Following Choline and Lecithin Administration 
Interpretation of the incidence and nature of the side effects 
following choline and lecithin administration is complicated by each 
investigator's selection of different treatment regimens. Gen-
erally, the longer a lecithin or choline preparation is given or the 
higher the dose that is given, the greater the incidence of side 
effects. The purity of the lecithin used; that is, the percentage 
of phosphatidylcholine that preparation contains,- will be a major 
factor in determining the amount of lecithin given. Depending on the 
supplier, phosphatidylcholine content ranges from 20 to 90%. 
Earlier clinical studies employed choline almost exclusively. Doses 
of 150 - 200 mg/kg/da (approximately 14 g/da) for 2 weeks (Growdon 
et ~, 1977) were typical. Side effects frequently encountered in-
cluded diarrhea, an unpleasant "fishy" body odor (probably reflec-
ting the trimethylamine formed from choline by intestinal bacteria) 
and a bitter taste (Zeisel et~, 1980a). 
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Figure 3. Plasma choline response to ingested choline and lecithin. 
Six adult human subjects ingested each of four diets (conmon foods 
high in choline, common foods low in choline diet plus breakfast 
supplement of 25 gm 80% pure egg lecithin and low-choline diet plus 
breakfast supplement of 25 gm 80% pure soy lecithin). Plasma 
samples were obtained at regular intervals and assayed were obtained 
at regular intervals and assayed for choline. Meal times are indi-
cated by arrows. Data are expressed as mean + SO. (By permission). 
Most of the reports describing experimental feeding of lecithin do 
not i nd i cate whether or not si de effects were experi enced. One 
should not assume that there were no side effects in these studies 
but might conclude that the likelihood of there being any major side 
effects was minimal. Zeisel et al (1980a) have reported that leci-
thin has fewer side effects than chol ine and does not possess a 
bitter taste. Minimal side effects were encountered such as indi-
gestion, weight gain and minor diarrhea, with no consistent mental 
changes or alterations of hematological or hepatic indices. These 
observations were derived from an experimental protocol that 
required the administration of 60-80 grams of lecithin (20% phos-
phatidylchol ine) for 6 weeks. Another study which employed 50-100 
grams of lecithin per day for 8-16 weeks also reported side effects 
of diarrhea. nausea, depression. "hot flashes" and weakness, but 
only in the patients who suffered from ataxia and who consumed the 
100 gram dose (Chamberlain et al, 1980). These doses and adminis-
tration periods are all higherthan the doses and administration 
periods employed by other investigators who make no mention of side 
effects: 25 g/ da x 2 weeks (Branchey et a 1, 1979), 24 g/ da x 8 
weeks (Barbeau, 1978), and 25 g/da x 1 day{Ziesel et al, 1980b). 
Additional studies have indicated that the source of---lecithin does 
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not affect its abil ity to rai se chol ine 1 evel sin brai n. Soybean 
and egg lecithins differ in terms of fatty acid composition; the 
former containing 72% polyunsaturates vs 20% (see figure). (Zeisel 
et al, 1980b; Magil et al, 1981). It is not known if the fatty acid 
composition infl uences Side effects. Experiments at Johnson Space 
Center will employ polyunsaturated soybean lecithin in accordance 
with current cl inical and nutritional preference. Based on these 
findings, a daily dose of 25 grams of soy lecithin (90% phospha-
tidyl chol ine) for 3 weeks was considered to possess minimal side 
effects if any. Selection of this dosage level was based on phar-
macodynamic studies as well (Section B). 
D. Methods of Preparation of Lecithin for Daily Consumption 
Although there have been reports that some individual s enjoy the 
taste of plain lecithin, most people prefer to disguise the taste by 
incorporating the lecithin into other preparations. Three prepar-
ations have been described and are detailed below: 
Preparation (No.1) 
Ingredients: 
Lecithin (daily dose up to 100g) 
1/2 cup water 
3 1/2 teaspoons polycose (or other sugar) 
1 cup milk 
1/2 cup vanilla ice cream 
2 teaspoons instant coffee 
Preparation: 
1. Mix lecithin and water in a blender 
(chop setting) 
2. Dissolve till a pudding consistency, 
then add milk, sugar and coffee 
3. Mix thoroughly, then add ice cream 
blend 
Enough to make 3-4 six-ounce drinks 
Formulate by Maureen Quirk, R.D. 
(From: Zi esel et~, 1980a) 
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Preparation (No.!) 
Up to 25 grams of lecithin as an emulsion 
in hot coffee and sugar 
(From: Branchey et~, 1979) 
Preparation (No.1) 
25 grams of lecithin mixed with Kool-Aid 
and taken in three divided doses. 
(From: Growdon et al, 1977) 
--
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Cingulate gyrus, 13 
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